Colorectal Cancer

>

Latest News

Non-Operative Management Does Not Compromise DRFS in pMMR Rectal Cancer
Non-Operative Management Does Not Compromise DRFS in pMMR Rectal Cancer

September 16th 2024

NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.

Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.
Ramucirumab Combo Shows No Significant OS Improvement in Metastatic CRC

September 15th 2024

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.
Atezolizumab Combo Improves Survival in Metastatic CRC

August 22nd 2024

CytoDyn intends to submit its final study protocol to the FDA, engage a clinical research organization, and complete preparatory work to initiate the phase 2 trial.
FDA Holds Meeting for Leronlimab Rationale, Dosing in CCR5+ MSS mCRC

August 14th 2024

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.
New HIV Guidelines Recommend Screening to Mitigate Anal Cancer Risk

August 12th 2024